Breaking News Instant updates and real-time market news.

AMRS

Amyris

$4.67

-0.1 (-2.10%)

, SEDG

SolarEdge

$45.13

-0.85 (-1.85%)

08:45
04/30/19
04/30
08:45
04/30/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Amyris (AMRS) 99.15% +1.43, SolarEdge (SEDG) 1.19% +0.72, Qutoutiao (QTT) 10.83% +0.36, Uxin Ltd (UXIN) 9.51% +0.20, Blackstone (BX) 0.52% +0.06, Frontier Communications (FTR) 9.24% +0.06, and U.S. Natural Gas Fund (UNG) 2.93% +0.01.

AMRS

Amyris

$4.67

-0.1 (-2.10%)

SEDG

SolarEdge

$45.13

-0.85 (-1.85%)

QTT

Qutoutiao

$7.17

-0.53 (-6.88%)

UXIN

Uxin

$2.79

-0.03 (-1.06%)

BX

Blackstone

$40.50

0.29 (0.72%)

FTR

Frontier Communications

$2.72

0.07 (2.64%)

UNG

United States Natural Gas Fund

$22.46

0.085 (0.38%)

  • 30

    Apr

  • 06

    May

  • 07

    May

  • 15

    May

  • 11

    Jun

AMRS Amyris
$4.67

-0.1 (-2.10%)

12/31/18
HCWC
12/31/18
NO CHANGE
Target $11
HCWC
Buy
Amyris news today a 'significant near-term milestone,' says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal maintains a Buy rating on Amyris with an $11 price target after the company entered into a long-term agreement with Xinfu for an upfront payment of $50M and an additional long-term annual share upside based on an existing nutritional product royalty arrangement. Amyris is capitalizing on its relationship with Xinfu to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this "high-margin" revenue stream while continuing to benefit from future royalty payments, Dayal tells investors in a research note. He thinks today's news should be viewed as a "timely delivery of a significant near-term milestone by the management team."
12/07/18
HCWC
12/07/18
NO CHANGE
HCWC
Amyris financing removes 'important overhang,' says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal reiterated a Buy rating and $11 price target on Amyris, noting that the company announced it has entered into definitive agreements for the sale of $60M of unsecured convertible senior notes, in a private placement with two investors. Dayal said this financing removes an "important overhang" for the company, and believes that Amyris is now positioned to focus on execution during 2019. The analyst added that he is looking forward to more information from the company during the last three weeks of this year, including the announcement of a Chinese licensing agreement.
02/05/19
HCWC
02/05/19
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright reiterates $11 target on Amyris after $255M cannabinoid deal
Amyris this morning announced a $255M collaboration agreement, its largest yet, with an unnamed partner, for cannabinoid development and licensing, H.C. Wainwright analyst Amit Dayal tells investors in a research note. The analyst reiterates a Buy rating on the shares with an $11 price target. The stock in morning trading is up 42%, or $1.33, to $4.49. Dayal believes the agreement calls for several molecules that will be targeting multiple products and end markets, with the first commercial production taking place in 18-24 months. He thinks the early applications are targeting opportunities in the skin care and beverage markets. Further, with an executed binding term sheet in place leading to the announcement, Dayal sees a "high probability" of the deal closing within the expected timeline. And since the non-psychoactive cannabidiol based molecules developed using Amyris' fermentation technology are likely to bypass the psychoactive tetrahydrocannabinol molecule pathway, the regulatory approval process "should not run afoul of the federal THC related restrictions," the analyst writes. He views today's announcement as an "important signal about the scalability" of Amyris' technology platform to enter large new markets very quickly. The analyst also believes the development timeline is "realistic given that product development has been accelerating at the company."
11/14/18
HCWC
11/14/18
NO CHANGE
Target $11
HCWC
Buy
Amyris price target lowered to $11 from $15 at H.C. Wainwright
H.C. Wainwright analyst Amit Dayal lowered his price target for Amyris to $11 to reflect a more conservative stance on forward projections, including removing around $40M of anticipated annual Vitamin E royalty revenues, following the company's revenue miss in Q3. The analyst, however, keeps a Buy rating on the shares.
SEDG SolarEdge
$45.13

-0.85 (-1.85%)

03/25/19
FBCO
03/25/19
INITIATION
Target $43
FBCO
Neutral
SolarEdge initiated with a Neutral at Credit Suisse
Credit Suisse analyst Maheep Mandloi started coverage of SolarEdge with a Neutral rating and a $43 price target. The analyst notes that the company is an industry leader with a strong balance sheet, 35%-plus gross margins in 2017/18, and the highest penetration in residential and commercial solar due to proprietary solar optimizer and inverter technology, with 50% of the U.S. residential market share. However, three recent acquisitions that could potentially help diversify out of the solar industry are not EPS accretive before 2021 and will be a drag on gross margins and capex requirements, he argues.
03/18/19
VERF
03/18/19
NO CHANGE
VERF
SolarEdge lost second 'material' U.S. executive in a week, says Vertical Group
Vertical Group analyst Gordon Johnson said in an email that he has confirmed that Teff Reed, the Senior Director of Field Services who was in charge of warranty issues and failure rates, no longer works at SolarEdge. Reed's departure marks the second "material" U.S. executive departure in under seven days following the exit of Amir Cohen, according to Johnson. Johnson, who said material U.S. executive departures are "concerning if one is still bullish on the company's fundamental outlook," has a Sell rating on SolarEdge shares.
03/12/19
VERF
03/12/19
NO CHANGE
VERF
Sell
SolarEdge head of U.S. sales has left company, says Vertical Group
Vertical Group analyst Gordon Johnson said in an email that he has confirmed with SolarEdge that Amir Cohen, the company's former VP of North America sales, has left the company. In his view and based on his checks regarding SolarEdge's sales and quality issues in the U.S. "this is not good," Johnson stated. Johnson has a Sell rating on SolarEdge shares.
02/12/19
BOFA
02/12/19
NO CHANGE
BOFA
First Solar, Canadian Solar likely to beat quarter estimates, says BofA/Merrill
BofA/Merrill analyst Brian Lee says that despite the strong year-to-date outperformance across the group, he would lean into solar stocks heading into Q4 earnings as he sees momentum likely to persist for stocks that can beat, namely First Solar (FLSR) and Canadian Solar (CSIQ). Fundamentally, the analyst expects a much more constructive tone from companies heading into 2019, and sees both companies as best positioned to beat given First Solar's better margins and Canadian Solar's project sales that consensus is not capturing. On the flipside, Lee reiterates a Sell rating on SolarEdge (SEDG), which he sees as having the highest idiosyncratic risk and lower estimates owing to recent M&A that appears both dilutive and a key investor focus point.
QTT Qutoutiao
$7.17

-0.53 (-6.88%)

04/16/19
SBSH
04/16/19
UPGRADE
Target $14
SBSH
Buy
Qutoutiao upgraded to Buy from Neutral at Citi
Citi analyst Alicia Yap upgraded Qutoutiao to Buy from Neutral while lowering her price target for the shares to $14 from $16. The analyst sees a better risk/reward profile with the shares down 24% since the March 29 secondary offering. Qutoutiao's user numbers were solid in March and possible further collaborations with Taobao merchants and Alibaba's marketing could allow the company to capitalize on user retention, Yap tells investors in a research note
03/06/19
KEYB
03/06/19
DOWNGRADE
KEYB
Sector Weight
Qutoutiao downgraded to Sector Weight from Overweight at KeyBanc
02/20/19
DBAB
02/20/19
DOWNGRADE
DBAB
Hold
Qutoutiao downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Hanjoon Kim downgraded Qutoutiao to Hold saying the risk/reward is balanced at current share levels.
02/15/19
UBSW
02/15/19
DOWNGRADE
Target $13.5
UBSW
Neutral
Qutoutiao downgraded to Neutral from Buy at UBS
UBS analyst Jerry Liu downgraded Qutoutiao to Neutral from Buy, telling investors in a research note that the share price has almost tripled since mid-December, possibly attributable to the strong momentum of the company's user expansion as well as Midu's initial success. Liu, who raised his price target to $13.50 from $11, says Qutoutiao's current price implies 2.8x2019E P/S, which he thinks represents a fair risk-reward balance between its user growth potential and margin pressure.
UXIN Uxin
$2.79

-0.03 (-1.06%)

04/24/19
04/24/19
NO CHANGE

Uxin mentioned cautiously again by J Capital
J Capital Research has published a follow-up report on its short call on Uxin to respond to the company's response to the firm's April 16 short report. In the follow-up, J Capital's Anne Stevenson-Yang writes in part: "Uxin's response on the number of cities covered - it says 900 - contradicts what Investor Relations told us just one week before the report." Reference Link
03/12/19
FBCO
03/12/19
INITIATION
Target $7.7
FBCO
Outperform
Uxin initiated with an Outperform at Credit Suisse
Credit Suisse initiated Uxin with an Outperform and $7.70 price target.
03/14/19
JPMS
03/14/19
NO CHANGE
Target $8
JPMS
Overweight
JPMorgan sees over 70% upside in Uxin, ups price target to $8
JPMorgan analyst Nick Lai raised his price target for Uxin to $8 from $7 following the company's better than expected Q4 results. The stock closed yesterday down 2c to $4.60. The analyst increased his revenue forecasts for 2019 and 2020 and believes Uxin will turn to profit in Q4 of 2019. For 2019, Lai forecasts intercity transaction will quadruple while believing same city should also surge by greater than 30%. He keeps an Overweight rating on Uxin shares.
04/16/19
04/16/19
NO CHANGE

Uxin exaggerates auto volumes by as much as 40%, says J Capital
J Capital Research analyst Anne Stevenson-Yang believes Uxin exaggerates the volume of auto sales its processes by as much as 40%. After speaking to dealers, former executives, and salespeople from competing companies, the analyst believes Uxin is "basically a Craigslist of autos," listing cars that are being offered on multiple websites, for free. Further, financial statements for Uxin's operating companies in China "show a staggering level of debt that puts the company at risk of collapse," Stevenson-Yang tells investors in a research note. She admits to not knowing how to ascribe a valuation to the stock since the company "is so dishonest." Investors should "race to the exits," says Stevenson-Yang. Uxin in early trading is up 1c to $3.06.
BX Blackstone
$40.50

0.29 (0.72%)

04/23/19
SBSH
04/23/19
NO CHANGE
SBSH
Citi adds Blackstone to Focus List, removes Chubb and Pioneer Natural
Citi added Blackstone (BX) to its US Focus List on the belief that the shares have more room to run. Blackstone could have "materially more upside," especially considering its "best-in-class" business model and widespread investor appeal, the firm's North America Research team says in a note. It removed Chubb (CB) and Pioneer Natural Resources (PXD) from the US Focus List due to analyst departures.
04/22/19
MSCO
04/22/19
NO CHANGE
Target $45
MSCO
Overweight
Blackstone price target raised to $45 from $40 at Morgan Stanley
Morgan Stanley analyst Michael Cyprys raised his valuation multiple on "sticky" management fee earnings at Blackstone and increased his price target on the stock to $45 from $40 following the company's announcement of plans to convert to a C-Corporation, stating that he believes the change from a partnership should unlock value by expanding the investor base that can participate. He believes multiple expansion should more than offset the expected 2%-5% hit to EPS over the next few years and 12%-13% longer-term hit from shifting to a corporate tax rate, said Cyprys, who keeps an Overweight rating on Blackstone shares.
04/15/19
SBSH
04/15/19
UPGRADE
Target $35
SBSH
Neutral
Citi upgrades Franklin Resources, Artisan to Neutral from Sell
Citi analyst William Katz upgraded both Franklin Resources (BEN) and Artisan Partners (APAM) to Neutral from Sell. The analyst raised his price target to $35 from $28 for the former and to $25 from $20 for the latter. Ahead of the Q1 earnings season, however, the analyst favors the Alternatives. His top picks are Och-Ziff Capital (OZM), Brookfield (BAM) and Blackstone (BX). Katz, though, is "tactically less negative" on the Traditional asset managers.
01/02/19
SUSQ
01/02/19
UPGRADE
Target $31
SUSQ
Positive
Crocs upgraded to Positive at Susquehanna
As reported previously, Susquehanna analyst Sam Poser upgraded Crocs (CROX) to Positive from Neutral. The analyst cited the recent repurchase and conversion of Blackstone's (BX) preferred stock position as it removes a substantial financial overhang from the company's capital structure and shifts more control of the business into the hands of existing and potential shareholders. In addition, the business continues to accelerate as processes and products improve and the brand gains traction, said Poser, who raised his price target to $31 from $25 on Crocs shares.
FTR Frontier Communications
$2.72

0.07 (2.64%)

02/19/19
RAJA
02/19/19
DOWNGRADE
RAJA
Market Perform
Frontier Communications downgraded to Market Perform at Raymond James
Raymond James analyst Frank Louthan downgraded Frontier Communications (FTR) to Market Perform from Outperform saying the negative Windstream (WIN) ruling will have a negative impact from a trading perspective. Louthan said rural ILECs tend to trade as a group and are overly correlated with each other regardless of their results.
02/19/19
RAJA
02/19/19
DOWNGRADE
RAJA
Market Perform
Frontier Communications downgraded to Market Perform at Raymond James
01/08/19
WELS
01/08/19
DOWNGRADE
Target $1.75
WELS
Underperform
Frontier downgraded to Underperform from Market Perform at Wells Fargo
Wells Fargo analyst Jennifer Fritzsche downgraded Frontier Communications (FTR) to Underperform and lowered her price target for the shares to $1.75 from $5.00. The analyst also downgraded the Rural Local Exchange Carrier sector to Underweight from Market Weight. Frontier has reportedly been working with an advisor on how it might handle upcoming debt maturities, Fritzsche tells investors in a research note. The debt seems to be pricing in a looming restructuring, which "could cause a scar on the RLEC industry," adds the analyst. Fritzsche remains concerned about Frontier's near term balance sheet obligations and believe "this is very much a debt story at this point."
01/08/19
WELS
01/08/19
DOWNGRADE
Target $11.25
WELS
Market Perform
Consolidated Communications downgraded to Market Perform at Wells Fargo
Wells Fargo analyst Jennifer Fritzsche downgraded Consolidated Communications to Market Perform from Outperform and lowered her price target for the shares to $11.25 from $13.50. The analyst also downgraded the Rural Local Exchange Carrier sector to Underweight from Market Weight. She believes Consolidated Communications has the ability to sustain its dividend. However, she is concerned that any sort of restructuring, or perception that a restructuring could occur with Frontier Communications (FTR), "could put a stain on the whole RLEC group." If Frontier has to do "some creative things" with its balance sheet, investors will look to who could be next and Consolidated Communications could be on that perceived list, Fritzsche tells investors in a research note.
UNG United States Natural Gas Fund
$22.46

0.085 (0.38%)

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.